41507-56-6

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 1-methyl-1H-imidazole-4-carboxylate is used as an intermediate in the synthesis of pharmaceutical compounds for its potential to contribute to the development of new medications with pharmacological properties.
Used in Agrochemical Development:
In the agrochemical industry, Ethyl 1-methyl-1H-imidazole-4-carboxylate is used as a component in the development of agrochemicals, likely due to its ability to form biologically active compounds that can be used in crop protection and other agricultural applications.
Used in Dye Production:
Ethyl 1-methyl-1H-imidazole-4-carboxylate is used in the production of dyes, where its chemical properties may contribute to the creation of new dye formulations with specific color characteristics or application properties.
Used in Materials Science:
In the field of materials science, Ethyl 1-methyl-1H-imidazole-4-carboxylate is utilized in the development of new materials, potentially due to its ability to form compounds with unique properties that can be applied in various material technologies.

InChI:InChI=1/C7H10N2O2/c1-3-11-7(10)6-4-9(2)5-8-6/h4-5H,3H2,1-2H3

Upstream product

• 23785-21-9 ethyl 1H-imidazole-4-carboxylate 
• 74-88-4 methyl iodide 
• 64-17-5 ethanol 
• 41716-18-1 1-methylimidazole-4-carboxylic acid 
• 74-89-5 methylamine 
• 32683-02-6 ethyl-2-aminocyano acetate 
• 54147-04-5 5-amino-1-methyl-1H-imidazole-4-carboxylic acid ethyl ester 

Downstream Products

• 129993-50-6 1-methylimidazole-4-carboxymethylamide 
• 1414579-64-8 4-methyl-3-(1-methyl-1H-imidazol-4-yl)-1-phenyl-1H-pyrazol-5-amine hydrochloride 
• 1414581-27-3 1-methyl-4-(4-methyl-5-(phenoxycarbonylamino)-1-phenyl-1H-pyrazol-3-yl)-3-(phenoxycarbonyl)-1H-imidazol-3-ium chloride 

Relevant academic research and scientific papers

Extension of Azine-Triazole Synthesis to Azole-Triazoles Reduces Ligand Field, Leading to Spin Crossover in Tris-L Fe(II)

The first examples of azole-Triazole Rat ligands, bidentate L4NMeIm(3-(1-methyl-1H-imidazol-4-yl)-5-phenyl-4-(p-Tolyl)-4H-1,2,4-Triazole) and L4SIm (4-(5-phenyl-4-(p-Tolyl)-4H-1,2,4-Triazol-3-yl)thiazole), have been prepared, by extension of the general synthesis used to access many examples of azine-Triazoles. The tris-L FeII complexes of the azine-Triazoles are consistently low spin (LS). As intended, these new azole-Triazole ligands provide lower field strengths, resulting in high-spin (HS) [FeII(L4NMeIm)3](BF4)2 (1·4H2O) and spin crossover (SCO) active [FeII(L4SIm)3](BF4)2 (2·0.5H2O). Single-crystal structure determinations revealed that at 100 K 1·solvents is HS whereas 2·solvents is LS. Solid-state variable temperature magnetic studies of air-dried crystals showed that the methylimidazole-Triazole complex 1·4H2O remains HS while the thiazole-Triazole complex 2·0.5H2O undergoes a two-step gradual SCO (T1/2 approximately 275 and 350 K). Variable-Temperature Evans method NMR studies of 2, in five different solvents (CD3NO2, CD3CN, CD3COCD3, CD2Cl2, and CDCl3) gave T1/2 values in a relatively narrow range, 214-259 K. These T1/2 values did not correlate with the solvent polarity index P′ (R2 = 0.25) but did correlate with the solvent basicity parameter SB (R2 = 0.90). Variable-Temperature UV-vis studies on a golden yellow CH3CN solution of 2, with monitoring of the d-d transition at 530 nm (? = 39 L mol-1 cm-1 at 293 K) while the solution was heated from 253 to 303 K, showed that the high-spin fraction increased from 0.51 to 0.77. Cyclic voltammetry studies in CH3CN revealed a Fe(III)/Fe(II) redox process that was reversible for 1 and irreversible for 2, with significant tuning of the Epa value: The methylimidazole-Triazole complex 1 is significantly easier to oxidize (0.46 V) than the thiazole-Triazole complex 2 (0.68 V; both vs 0.01 M Ag/AgNO3).

IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Synthesis and structure-activity relationships of new (5R,8R,10R)-ergoline derivatives with antihypertensive or dopaminergic activity

A series of new (5R,8R,10R)-ergoline derivatives was synthesized, and their antihypertensive and dopaminergic activities were tested in conscious spontaneously hypertensive rats and in rats with unilateral 6- hydroxydopamine-induced lesions of the substantia nigra. (5R,8R,10R)-6- Alkyl-8-ergolinemethanols, prepared from the corresponding ergolinecarboxylates, were converted to the tosylates, which were treated with various five-membered heterocycles containing nitrogen atoms to afford the new ergolines. (5R,8R,10R)-8-(1,2,4-Triazol-1-ylmethyl)-6-methylergoline (4s, maleate: BAM-1110) exhibited potent dopaminergic activity, about 18- fold greater than that of bromocriptine mesylate. (5R,8R,10R)-8-(1,2,4- Triazol-1-ylmethyl)-6-propylergoline (8b, fumarate: BAM-1602) showed extremely potent dopaminergic activity, being about 220 and 1.15 times more active than bromocriptine mesylate and pergolide mesylate, respectively. Several compounds exhibited potent antihypertensive activity. Structure- activity relationships for antihypertensive and dopaminergic activities are discussed.